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ORIGINAL ARTICLE
Short- and long-term glucocorticoid treatment
enhances insulin signalling in human subcutaneous
adipose tissue
LL Gathercole, SA Morgan, IJ Bujalska, PM Stewart and JW Tomlinson
Centre for Endocrinology, Diabetes and Metabolism, School of Clinical and Experimental Medicine, Institute of Biomedical
Research, University of Birmingham, Birmingham, UK
Background: Endogenous or exogenous glucocorticoid (GC) excess (Cushing’s syndrome) is characterized by increased
adiposity and insulin resistance. Although GCs cause global insulin resistance in vivo, we have previously shown that GCs are able
to augment insulin action in human adipose tissue, contrasting with their action in skeletal muscle. Cushing’s syndrome
develops following chronic GC exposure and, in addition, is a state of hyperinsulinemia.
Objectives: We have therefore compared the impact of short- (24h) and long-term (7 days) GC administration on insulin
signalling in differentiated human adipocytes in the presence of low or high concentrations of insulin.
Results: Both short- (24h) and long-term (7 days) treatment of chub-s7 cells with dexamethasone (Dex) (0.5 mM) increased
insulin-stimulated pTyr612IRS1 and pSer473akt/PKB, consistent with insulin sensitization. Chronic high-dose insulin treatment
induced insulin resistance in chub-s7 cells. However, treatment with both high-dose insulin and Dex in combination still caused
insulin sensitization.
Conclusions: In this human subcutaneous adipocyte cell line, prolonged GC exposure, even in the presence of high insulin
concentrations, is able to cause insulin sensitization. We suggest that this is an important mechanism driving adipogenesis and
contributes to the obese phenotype of patients with Cushing’s syndrome.
Nutrition and Diabetes (2011) 1, e3; doi:10.1038/nutd.2010.3; published online 31 January 2011
Keywords: glucocorticoids; insulin signalling; obesity; cortisol; adipocyte
Introduction
The global epidemics of obesity and type 2 diabetes have
heightened the need to understand the molecular mecha-
nisms that contribute to their pathogenesis. Patients with
Cushing’s syndrome develop central obesity, insulin resis-
tance and in some cases type 2 diabetes; this has focused
attention on the potential pathogenic role of the hypo-
thalamo–pituitary–adrenal axis, and endogenous glucocorti-
coid (GC) production and metabolism in simple obesity.
Furthermore, the widespread therapeutic use of GCs1 means
that understanding the mechanisms that lead to their
adverse event profile has a huge clinical relevance.
GCs cause global insulin resistance.2 However, there is
increasing evidence to suggest that GCs may have tissue-
specific effects on insulin action.3,4 We have shown
that short-term (24h) treatment with the synthetic GCs,
dexamethasone (Dex) and cortisol, causes insulin sensiti-
zation in human adipose tissue,3 in cells cultured in the
absence of insulin. Additionally, we have shown that this
is functionally important and augments insulin-stimulated
glucose uptake.3 This contrasts with the induction of
insulin resistance in skeletal muscle.5,6 Although these
observations have contradicted the widely held dogma that
GCs cause global ‘pan-tissue’ insulin resistance, it remains
plausible that prolonged administration of GCs may have
differing effects on insulin signalling. In addition, GC excess
leads to hyperinsulinemia,7 which may further fuel insulin
resistance,8 and high concentrations of insulin may modify
the effect of GCs in adipose tissue. We have therefore deter-
mined the impact of short- and long-term GC treatment on
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insulin signalling in adipose tissue at differing insulin
concentrations.
Materials and methods
Chub-s7 cell line
Proliferating chub-s7 cells were cultured in Dulbecco’s
MEM/Nutrient Mixture F-, DMEM-F12 (Sigma, Poole, UK)
with 10% FCS and seeded into 12-well plates and grown until
confluent. Cells were differentiated in chemically defined
DMEM-F12 media for 14 days.3 Differentiated chub-s7 cells
were cultured in media (DMEM-F12) without additives for
24h. Cells were then incubated with either 5 or 50nM
insulin, with or without 0.5 mM Dex for either 24h or
7 days. We have previously cultured cells without insulin
in the presence and absence of Dex,3 and the purpose of
this study was not only to examine the impact of long-
term Dex treatment, but also to replicate an environment
that more closely resembles the physiological situation
and includes high insulin concentrations. In all cell culture
experiments investigating insulin signalling cascade protein
phosphorylation, and in order to activate the insulin
signalling cascade, media was spiked with human insulin
(0.1 mgml1, Sigma) for the final 15min of the treatment
period.
RNA extraction, reverse transcription and real-time PCR
Total RNA was extracted using the Tri-Reagent system and
mRNA levels or target genes were determined using an ABI
7500 sequence real-time PCR detection system (Perkin-Elmer
Applied Biosystems, Warrington, UK). ‘Assay on demand’
probes and primers (Perkin-Elmer Applied Biosystems) were
used (18S ribosomal RNA pre-optimized control probe).9
Data were obtained as ct values (ct¼ cycle number at which
logarithmic PCR plots cross a calculated threshold line)
and used to determine Dct values (Dct¼ (ct of the target
gene)(ct of the housekeeping gene)). Data are expressed
as arbitrary units using the following transformation:
expression (¼104 (2Dct) arbitrary units (AU). When used,
fold changes were calculated using the following equation:
fold increase¼2difference in Dct.
Protein extraction and immunoblotting
Soluble protein extraction and quantification was performed
as previously reported.3 Fifteen micrograms of protein
sample was resolved on a 12.5% SDS-PAGE gel and trans-
ferred onto a nitrocellulose membrane, Hybond ECL
(GE Healthcare, Chalfont St Giles, UK). Primary (anti-PKB/akt,
IRS 1 and IRS 2, Upstate, Dundee, UK; anti-pSer473akt/PKB,
R&D Systems, Abingdon, UK; anti-pTyr612IRS1, Biosource,
Nivelle, Belgium) and secondary antibodies (Dako, Glostrop,
UK) were used at a dilution of 1/1000 as described previously.3
Membranes were re-probed for b-actin (antibody dilution
1/5000, Abcam plc, Cambridge, UK). Bands were quantified
with Genesnap (Syngene, Cambridge, UK).
Statistical analysis
Where data were normally distributed, unpaired Student’s
t-test was used to compare single treatments with control.
If normality tests failed, then non-parametric tests were
used. One-way analysis of variance on ranks was used to
compare multiple treatments, doses or times (SigmaStat 3.1,
Systat Software Inc., Point Richmond, CA, USA). Statistical
analysis on real-time PCR data was performed on mean Dct
values and not on fold changes.
Results
Short-term Dex treatment (24 h) and insulin signalling in
chub-s7 cells
Dex (24h, 0.5 mM) increased IRS2 and PI3K mRNA expression
in the presence of both 5 and 50nM insulin (Table 1).
Insulin-stimulated pTyr612IRS1 increased following Dex
pre-treatment, but this was less marked in the presence
of high-dose insulin. Total IRS1 protein levels were not
altered (Figures 1a and b), but IRS2 protein was increased
Table 1 mRNA expression as measured by real-time PCR in chub-s7 cells treated with insulin (low 5nM or high 50 nM dose) with or without Dex (0.5 mM) for
either 24 h or 7 days
Gene Short-term (24 h) Long-term (7 d)
5 nM Insulin 50 nM Insulin 5 nM Insulin 50 nM Insulin
Control 0.5 mM Dex Control 0.5 mM Dex Control 0.5 mM Dex Control 0.5 mM Dex
FABP4 76.93±68.80 89.66±50.43 67.37±36.10 110.72±63.02 52.86±17.24 124.00±15.17 47.90±24.31 150.92±22.39a
IRS-1 0.28±0.09 0.47±0.17 0.45±0.04 0.48±0.03 0.46±0.06 0.62±0.12 0.39±0.09 0.57±0.14
IRS-2 0.59±0.19 1.61±0.49a 0.79±0.18 2.53±0.26a 0.70±0.09 2.08±0.40a 1.19±0.26 2.11±±0.43a
PI3 K 0.88±0.19 2.87±0.85a 1.38±0.27 4.73±0.68b 1.48±0.14 5.84±1.69a 1.72±0.52 6.56±1.87b
AKT-1 2.51±0.88 1.51±0.27 1.77±0.38 1.98±0.48 1.22±0.39 1.58±0.35 1.61±0.34 1.58±0.32
AKT-2 0.85±0.22 0.49±0.15 0.85±0.18 0.57±0.14 0.70±0.36 0.65±0.24 0.62±0.13 0.80±0.18
Abbreviations: d, days; Dex, dexamethasone. aPo0.05. bPo0.01 vs control. Data are presented as mean arbitrary units±s.e. from n¼3–5 experiments, with lower
values representing higher mRNA expression.
Glucocorticoids and insulin signalling
LL Gathercole et al
2
Nutrition and Diabetes
(Figures 1c and d). Further downstream, Dex treatment
for 24h increased insulin-stimulated pS473akt/PKB, with no
alteration in total akt/PKB levels in the presence of either
5 or 50nM insulin (Figures 1e and f). In cells that were not
spiked with insulin to activate the insulin signalling, Dex pre-
treatment alone did not alter IRS1 or akt/PKB phosphorylation.
Long-term Dex treatment (7 days) and insulin signalling in
chub-s7 cells
Only in the presence of high-dose insulin (50nM) did
Dex increase FABP4 mRNA expression (Table 1). Seven-day
Dex treatment increased IRS2 and PI3K mRNA expres-
sion in the presence of both 5 and 50nM insulin (Table 1).
Insulin-stimulated pTyr612IRS1 levels increased following
Dex pre-treatment at both doses of insulin (5 and 50nM), but
total IRS1 protein levels did not change (Figures 1a and b).
However, 7 days treatment with Dex increased IRS2 protein
levels (Figures 1c and d). Insulin-stimulated pS473akt/PKB in
the presence of either 5 or 50nM insulin increased following
chronic Dex treatment, without changing the total akt/PKB
protein levels (Figures 1e and f).
Insulin treatment and insulin signalling in chub-s7 cells
Although not the major purpose of the study, we were able
to compare the effects of 5 and 50nM insulin pre-treatment
and the duration of pre-treatment on the ability of insulin to
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Figure 1 The effect of short- (24 h) and long-term (7 days) treatment of differentiated chub-s7 cells with dexamethasone (D, 0.5 mM) on insulin-stimulated
activation of the insulin signalling cascade: (a, b) IRS1 and p612TyrIRS1; (c, d) IRS2; (e, f) akt/PKB and pSer473akt/PKB. Cells were co-incubated with either low
insulin (5 nM) (a, c, e) or high insulin (50 nM) (b, d, f) concentrations. Graphs shown are the mean of n¼3–5 experiments±s.e., with western blots quantified
against b-actin; representative western blots are shown inserted (*Po0.05, **Po0.01 vs control; white bars¼ control (C) and black bars¼dexamethasone (D)).
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activate the insulin signalling cascade. Basal samples without
any additives were not available for comparison, but have
been reported previously.3
In comparison with 24h treatment, 7-day exposure to
5nM insulin increased PI3K expression, but decreased
akt1/PKB expression. There were no significant differences
in gene expression between cells treated with 50nM insulin
for either 24h or 7 days (Table 1).
Chronic exposure to high doses of insulin is known to
cause insulin resistance. In agreement with this, 7 days
(as compared with 24h) treatment with high-dose insulin
(50nM) decreased insulin-stimulated pTyr612IRS1 and
akt/PKB protein levels without changing total IRS2 protein
expression (Figure 2).
Discussion
We have demonstrated that both short-term (24h) and
prolonged (7 days) treatment with GCs have similar effects
on insulin action. In both situations, GCs cause insulin
sensitization, as evidenced by enhanced insulin-stimulated
pTyr612IRS1 and pS473akt/PKB levels, without altering total
IRS1 or akt/PKB expression. Also, IRS2 mRNA and protein
expression increased.
The effects of GCs on the adipose tissue are complex.
Although they promote adipocyte differentiation,10 they
also drive lipolysis.11 The impact of GCs on insulin signalling
has only been studied in a small number of studies using
human models. In omental cells, GCs decrease insulin-
stimulated glucose uptake, but are without effect in
subcutaneous (s.c.) cells.12 However, detailed analysis of
the insulin signalling cascade was not performed in this
study. We have shown that GCs enhance insulin signalling
in a human s.c. cell line and in primary cultures of human
s.c. adipocytes, and that insulin-stimulated glucose uptake is
enhanced by GC pre-treatment.3 More recently, studies
endorsing our published data have shown that Dex treat-
ment (48h only) in human isolated pre-adipocytes causes
insulin sensitization with increased IRS1 and akt/PKB
phosphorylation.4 Our data extend these findings and
suggest that chronic GC exposure (7 days) is also able to
insulin-sensitize human adipose tissue. However, there are
limitations with the models that have been used. In our own
studies, we have used an immortalized human s.c. adipocyte
cell line. In previous papers differentiated cultured adipo-
cytes have been used, and in others intact isolated adipo-
cytes. All these different methodologies can make data
difficult to interpret; however, there still appears to be an
emerging consensus that GCs, far from causing insulin
resistance in adipose tissue, may actually cause insulin
sensitization. A further important caveat is that these are
systems examined in isolation and clinical studies are
needed to determine the impact of GCs on insulin action
in human adipose tissue in vivo.
Species specificity of response is likely to underpin
the discrepancy in observations between rodent models
and human studies. Rodent models have demonstrated
GC-induced insulin resistance in adipose tissue.4,13,14 How-
ever, rodents do not develop the classic Cushing’s phenotype
that is observed in humans in response to GC administra-
tion, and indeed can suffer from weight loss.15
The results of our study add weight to the body of evidence
supporting tissue-specific and species-specific regulation of
insulin action by GCs. The precise molecular mechanisms
remain to be determined. GCs regulate FoxO1A and FoxO3A
in rodents and humans,16,17 and it has been suggested that
the GC induction of these transcription factors may lead
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to increased IRS1 expression.4 However, we observed no
increases in IRS1 mRNA or protein expression even after 7
days of GC treatment. We did not examine expression levels
of FoxO1A or FoxO3A. A consistent finding across many
studies is GC induction of IRS2.3–5,17 This occurs in adipose
tissue (cell lines, primary cultures, and in both s.c.and
omental depots) and skeletal muscle, but is not a consistent
finding in rodents.18 Although in some tissues this may be
a compensatory mechanism to try to augment insulin
signalling in the face of insulin resistance, in human adipose
tissue it represents an additional mechanism by which
GCs enhance insulin signalling.
Cushing’s syndrome is a state of hyperinsulinemia,7 and
high insulin concentrations are a cause of insulin resis-
tance;8,19,20 Our data endorse this in human adipose tissue.
Chronic insulin treatment causes phosphorylation of IRS1
at a number of serine residues (including serine 302, 307, 612
and 623; rat numbering) and inhibits function.8,20 The aim
of our study was not to look specifically at the effect of
insulin administration on specific phosphorylation patterns;
however, in our chub-s7 model, 7-day administration of
high-dose insulin (50nM) did induce insulin resistance.
When we incubated GCs with both 50 and 5nM insulin
(concentrations that are probably in excess of those seen in
patients with Cushing’s syndrome), we still observed insulin
sensitization, suggesting that, in human adipose tissue, the
impact of GC treatment is able to overcome the insulin-
induced insulin resistance.
Our observations are relevant to patients with Cushing’s
syndrome. GC-induced adipose tissue insulin sensitization,
even in the context of hyperinsulinaemia, will further
enhance adipocyte differentiation and lipid accumulation.
The depot specificity of action in human adipose tissue
remains an important and unanswered question. Patients
with Cushing’s syndrome develop more marked central
adiposity, although s.c. fat mass also increases.21 Our
observations offer an explanation for the increase in s.c.
adiposity associated with GC excess. Further investigations
to determine the precise molecular events underpinning the
tissue specificity of response are now warranted. A better
understanding of these mechanisms raises the prospect
for the development of novel classes of GC that are
therapeutically efficacious, but do not drive adiposity.
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